Vixarelimab
KPL-716-C201
Phase 2 small_molecule completed
Quick answer
Vixarelimab for Prurigo Nodularis is a Phase 2 program (small_molecule) at Kiniksa Pharmaceuticals International, plc with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Kiniksa Pharmaceuticals International, plc
- Indication
- Prurigo Nodularis
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- completed